- Home
- JAKK vs NTHI Comparison
JAKK vs NTHI Comparison
Compare JAKK & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAKK
- NTHI
- Stock Information
- Founded
- JAKK 1995
- NTHI 2008
- Country
- JAKK United States
- NTHI United States
- Employees
- JAKK N/A
- NTHI N/A
- Industry
- JAKK Recreational Games/Products/Toys
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- JAKK Consumer Discretionary
- NTHI Health Care
- Exchange
- JAKK Nasdaq
- NTHI Nasdaq
- Market Cap
- JAKK 206.8M
- NTHI 211.9M
- IPO Year
- JAKK 1996
- NTHI N/A
- Fundamental
- Price
- JAKK $16.81
- NTHI $10.49
- Analyst Decision
- JAKK Strong Buy
- NTHI
- Analyst Count
- JAKK 3
- NTHI 0
- Target Price
- JAKK $36.67
- NTHI N/A
- AVG Volume (30 Days)
- JAKK 110.2K
- NTHI 40.6K
- Earning Date
- JAKK 10-30-2025
- NTHI 11-19-2025
- Dividend Yield
- JAKK 5.96%
- NTHI N/A
- EPS Growth
- JAKK N/A
- NTHI N/A
- EPS
- JAKK 0.53
- NTHI N/A
- Revenue
- JAKK $574,298,000.00
- NTHI $59,990.00
- Revenue This Year
- JAKK N/A
- NTHI N/A
- Revenue Next Year
- JAKK $4.06
- NTHI N/A
- P/E Ratio
- JAKK $31.65
- NTHI N/A
- Revenue Growth
- JAKK N/A
- NTHI N/A
- 52 Week Low
- JAKK $15.50
- NTHI $3.20
- 52 Week High
- JAKK $35.79
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- JAKK 34.01
- NTHI N/A
- Support Level
- JAKK $15.51
- NTHI N/A
- Resistance Level
- JAKK $17.05
- NTHI N/A
- Average True Range (ATR)
- JAKK 0.70
- NTHI 0.00
- MACD
- JAKK -0.31
- NTHI 0.00
- Stochastic Oscillator
- JAKK 29.42
- NTHI 0.00
About JAKK JAKKS Pacific Inc.
Jakks Pacific Inc is a multi-product line, multi-brand toy company that designs, produces, markets, sells and distributes toys and related kid-targeted consumer products, inclusive of kids indoor and outdoor furniture, costumes and various product lines in the sporting goods and home furnishings space. Its products offering include Traditional toys and electronics such as Action figures, Toy vehicles, Dolls and accessories, Ride-on toys, Toys for pets, and others. The company's products have been divided into two segments: (i) Toys/Consumer Products and (ii) Costumes.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).